Positive phase2 results reported for RPC1063 in relapsing MS

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Positive phase2 results reported for RPC1063 in relapsing MS

Postby MSUK » Tue Jun 10, 2014 2:34 am

Receptos, Inc. announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis (RMS) met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development..... Read More - http://www.ms-uk.org/RPC1063
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2212
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service